Generic Name and Formulations:
C1 esterase inhibitor (human) 2000 IU, 3000 IU; lyophilized pwd for SC inj after reconstitution; preservative-free.
CSL Behring, LLC
Indications for HAEGARDA:
Routine prophylaxis to prevent hereditary angioedema (HAE) attacks in adolescent and adult patients.
Adults and Children:
Rotate inj sites. Give by SC inj (eg, abdominal area, other SC sites). 60 IU/kg twice weekly (every 3 or 4 days).
Discontinue and treat if severe hypersensitivity reactions occur. Have epinephrine inj available. Risk of thromboembolism events. Contains human plasma; monitor for possible infection transmission (eg, viruses, Creutzfeldt-Jakob disease agent). Pregnancy. Nursing mothers.
Inj site reaction, hypersensitivity, nasopharyngitis, dizziness.
To report infections that may have been transmitted by Haegarda, call (866) 915-6958.
Sign Up for Free e-newsletters
- CHEMO-SUPPORT: A Nursing Intervention to Relieve Chemotherapy Symptom Burden
- A Witness to Letting Go: Nursing Care at the End of Life
- Sexual Quality of Life Decreased During, After Chemotherapy for Digestive Cancers
- Androgen-Deprivation Therapy for Prostate Cancer May Cause Nocturia, Sleep Disturbance
- Presence of Iris Pigmented Lesions Indicates Melanoma Risk
- Various Aspects of Palliative Care Focus Associated With Different Outcomes In Cancer
- Cost vs Benefits: The Controversy Over Proton Beam Radiotherapy
- Patient Expectations at Odds With Actual Outcomes for Radiotherapy in Breast Cancer
- Patients Desire More Online Tools and Access
- Managing Chemo Brain in Pediatric Survivors of Childhood Cancer
- Ciprofloxacin Plus Doxycycline Reduces Infection Rate in Multiple Myeloma Post-ASCT
- Prognostic Significance of Epidermal Growth Factor Receptor Expression in Glioma Patients
- Fathers Can Pass Inherited Ovarian Cancer Risk to Daughters
- Modified XELIRI Noninferior to FOLFIRI for OS in Metastatic Colorectal Cancer
- Nabilone Improves Cancer-Associated Anorexia in Lung Cancer
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|